Discuss CJC-1295 NO DAC + Ipamorelin on glp1chat
Join the forum to discuss research with other members.
At a glance
This pair uses a short-acting GHRH-related signal and ipamorelin's ghrelin-related signal to study growth hormone release. The no-DAC peptide is not the long-acting DAC form, and the response to both together needs its own evidence.
The no-DAC part is intended to provide a shorter growth-hormone-releasing message, while ipamorelin works through a second, ghrelin-related receptor. Researchers would examine whether the two signals change the pituitary's hormone pulse. This is not the long-acting DAC formulation, and the shorter exposure matters. Findings for either ingredient alone do not establish the combined result.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of CJC-1295 NO DAC + Ipamorelin.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
| Week | Daily Dose (mcg each) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg each | 3 units (0.03 mL) |
| Weeks 3–4 | 150 mcg each | 4.5 units (0.045 mL) |
| Weeks 5–6 | 200 mcg each | 6 units (0.06 mL) |
| Weeks 7–12 | 250–300 mcg each | 7.5–9 units (0.075–0.09 mL) |
Frequency: Inject once daily subcutaneously, typically before bed or upon waking[4]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support pulsatile GH release through synergistic GHRH + GHS stimulation[4].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–300 mcg of each peptide daily with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 100 mcg each peptide daily; increase by ~50 mcg every 1–2 weeks as tolerated.
- Target: 200–300 mcg each peptide daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Typically before bed or upon waking; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~28 days; avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[7].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7][8].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[9].
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (CJC-1295 NO DAC + Ipamorelin, 10 mg blend each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 5 vials
-
Insulin Syringes (U-100, 30- or 50-unit preferred for low volumes):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
PubMed — Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
PubMed — Once-daily CJC-1295 normalizes growth in GHRH knockout mouse (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
PubMed — Ipamorelin, the first selective growth hormone secretagogue (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
PMC — Beyond the androgen receptor: GH secretagogues in body composition management (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
PubMed — Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
PubMed — Ipamorelin GH pulse kinetics and timing studies (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 09
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Source document
Frontiers in Endocrinology — Growth hormone secretagogues: history and clinical applications (opens in a new tab)www.frontiersin.org
Back to overview ↑ - 12
Continue exploring
Related topics are not interchangeable compounds or formulations.